Pegvisomant in acromegaly: an update

BACKGROUND: In 2007, we published an opinion document to review the role of pegvisomant (PEG) in the treatment of acromegaly. Since then, new evidence emerged on the biochemical and clinical effects of PEG and on its long-term efficacy and safety. AIM: We here reviewed the emerging aspects of the us...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Endocrinol Invest
Autores principales: Giustina, A., Arnaldi, G., Bogazzi, F., Cannavò, S., Colao, A., De Marinis, L., De Menis, E., Degli Uberti, E., Giorgino, F., Grottoli, S., Lania, A. G., Maffei, P., Pivonello, R., Ghigo, E.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer International Publishing 2017
Materias:
Review
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5443862/
https://ncbi.nlm.nih.gov/pubmed/28176221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40618-017-0614-1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares